EA202091397A1 - Бензохинолоновые ингибиторы vmat2 - Google Patents

Бензохинолоновые ингибиторы vmat2

Info

Publication number
EA202091397A1
EA202091397A1 EA202091397A EA202091397A EA202091397A1 EA 202091397 A1 EA202091397 A1 EA 202091397A1 EA 202091397 A EA202091397 A EA 202091397A EA 202091397 A EA202091397 A EA 202091397A EA 202091397 A1 EA202091397 A1 EA 202091397A1
Authority
EA
Eurasian Patent Office
Prior art keywords
benzoquinolone
vmat2 inhibitors
vmat2
inhibitors
methods
Prior art date
Application number
EA202091397A
Other languages
English (en)
Inventor
Андреас Соммер
Чэнчжи Чжан
Original Assignee
Ауспекс Фармацетикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ауспекс Фармацетикалс, Инк. filed Critical Ауспекс Фармацетикалс, Инк.
Publication of EA202091397A1 publication Critical patent/EA202091397A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение относится к новым бензохинолоновым ингибиторам VMAT2, их фармацевтическим композициям и способам их применения.
EA202091397A 2013-01-31 2014-01-28 Бензохинолоновые ингибиторы vmat2 EA202091397A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361758861P 2013-01-31 2013-01-31

Publications (1)

Publication Number Publication Date
EA202091397A1 true EA202091397A1 (ru) 2020-09-04

Family

ID=51262872

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201500801A EA201500801A1 (ru) 2013-01-31 2014-01-28 Бензохинолоновые ингибиторы vmat2
EA202091397A EA202091397A1 (ru) 2013-01-31 2014-01-28 Бензохинолоновые ингибиторы vmat2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201500801A EA201500801A1 (ru) 2013-01-31 2014-01-28 Бензохинолоновые ингибиторы vmat2

Country Status (11)

Country Link
US (4) US20160068526A1 (ru)
EP (3) EP3770159A1 (ru)
JP (3) JP2016506957A (ru)
AU (4) AU2014212586A1 (ru)
BR (1) BR112015017878A2 (ru)
CA (1) CA2899707A1 (ru)
EA (2) EA201500801A1 (ru)
HK (1) HK1219095A1 (ru)
IL (3) IL240146A0 (ru)
MX (2) MX2015009719A (ru)
WO (1) WO2014120654A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2013318182C1 (en) 2012-09-18 2022-01-20 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
MX369956B (es) 2013-12-03 2019-11-27 Auspex Pharmaceuticals Inc Metodos para preparar compuestos de benzoquinolina.
AU2015209330A1 (en) * 2014-01-27 2016-07-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
IL305352A (en) 2015-03-06 2023-10-01 Auspex Pharmaceuticals Inc Methods for treating abnormal movement disorders
US10065952B2 (en) 2015-10-30 2018-09-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
CA3051829A1 (en) * 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
US10954235B2 (en) 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
JP7250006B2 (ja) 2017-09-21 2023-03-31 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
BR112021000019A2 (pt) 2018-08-15 2021-04-06 Neurocrine Biosciences Inc. Métodos para administração de certos inibidores de vmat2
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CR20230448A (es) 2021-03-22 2023-10-27 Neurocrine Biosciences Inc Inhibidores de vmat2 y métodos de uso

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) 1958-04-15 Quinolizine derivatives
US2843591A (en) * 1958-07-15 Method for preparing same
US3045021A (en) 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
DE69535592T2 (de) * 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
PL2012833T3 (pl) * 2006-05-02 2015-05-29 Univ Pennsylvania Znakowane radiologicznie pochodne dihydrotrabenazyny i ich zastosowanie jako środki do obrazowania
US8039627B2 (en) * 2006-11-08 2011-10-18 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
US8053578B2 (en) * 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
AU2009303758B8 (en) * 2008-09-18 2015-02-19 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20100113496A1 (en) * 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂

Also Published As

Publication number Publication date
US20210355120A1 (en) 2021-11-18
EA201500801A1 (ru) 2016-01-29
HK1219095A1 (zh) 2017-03-24
AU2014212586A1 (en) 2015-08-06
US20200165240A1 (en) 2020-05-28
US20160068526A1 (en) 2016-03-10
EP2951178A4 (en) 2016-07-06
IL279682A (en) 2021-03-01
IL240146A0 (en) 2015-09-24
BR112015017878A2 (pt) 2017-07-11
WO2014120654A1 (en) 2014-08-07
AU2021201629A1 (en) 2021-04-08
MX2020001756A (es) 2020-07-28
EP3770159A1 (en) 2021-01-27
AU2018203477A1 (en) 2018-05-31
JP2019048829A (ja) 2019-03-28
JP2021100941A (ja) 2021-07-08
AU2019268062A1 (en) 2019-12-12
US20180208592A1 (en) 2018-07-26
MX2015009719A (es) 2016-08-08
CA2899707A1 (en) 2014-08-07
IL267154A (en) 2019-08-29
EP2951178A1 (en) 2015-12-09
JP2016506957A (ja) 2016-03-07
EP3421469A1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA201692269A1 (ru) Новые композиции, их использование и способы получения
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201591962A1 (ru) Ингибиторы акк и их применение
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201591931A1 (ru) Композиции оксабициклогептанов и оксабициклогептенов